The impact of type 2 diabetes on the cardiovascular system in patients with rheumatoid arthritis
N. Yu. Tikhomirova,
O. I. Zhdamarova,
A. Yu. Selimov,
L. N. Eliseeva,
I. P. Sysoeva,
E. S. Kameneva,
N. P. Belozerova https://doi.org/10.33667/2078-5631-2025-28-59-66
Abstract
The aim. To study the effect of type 2 diabetes mellitus on the state of the cardiovascular system in patients with rheumatoid arthritis.
Materials and methods. Patients diagnosed with RA were included in the study in the order of their appointment with a rheumatologist and, depending on the presence of such a concomitant disease as type 2 diabetes mellitus, were divided into 2 groups: group 1 (n=262) – patients with RA, group 2 (n=53) – patients with RA and type 2 diabetes. Further, all the examined underwent a comprehensive laboratory and instrumental examination.
Results. Among patients with RA and type 2 diabetes, the body mass index (32,4±0,89 vs 28,3±0,28, р < 0,0001) and the relative wall thickness of the left ventricle (0,446±0,01 vs 0,42±0,004, р=0,04), the level of leukocytes (8,93±0,33 vs 7,24±0,17, р=0,0002) and neutrophils (63,16±1,76% vs 56,7±1,02%, р=0,02), NLR indices (2,92±0,33 vs 2,17±0,12, р=0,01), SII (925,5±146,8 vs 648,7±47,31, р=0,02), SIRI (1,98±0,19 vs 1,42±0,09, р=0,01) and significantly lower total cholesterol (4,88±0,19 vs 5,7±0,09, р=0,0002), low-density lipoproteins (2,86±0,26 vs 3,75±0,13, р=0,007), high-density lipoproteins (1,185±0,06 vs 1,55±0,04, р=0,003).
Conclusions. The presence of type 2 diabetes mellitus in patients with rheumatoid arthritis has a multidirectional effect on the state of the cardiovascular system. These results may have important implications for the management and treatment of patients with a combination of rheumatoid arthritis and type 2 diabetes mellitus.
About the Authors
N. Yu. Tikhomirova
Kuban State Medical University
Russian Federation
Russian Federation
Tikhomirova Nadezhda Yu., PhD Med, associate professor at Dept of Faculty Therapy
Krasnodar
O. I. Zhdamarova
Kuban State Medical University
Russian Federation
Russian Federation
Zhdamarova Olga Il., PhD Med, senior laboratory assistant at Dept of Faculty Therapy
Krasnodar
A. Yu. Selimov
Kuban State Medical University
Russian Federation
Russian Federation
Selimov Albert Yu., postgraduate student at Dept of Faculty Therapy
Krasnodar
L. N. Eliseeva
Kuban State Medical University
Russian Federation
Russian Federation
Eliseeva Lyudmila N., Dr Med Sci (habil.), professor, head of Dept of Faculty Therapy
Krasnodar
I. P. Sysoeva
Regional clinical Hospital No. 2
Russian Federation
Russian Federation
Sysoeva Irina P., head of the Clinical Diagnostic Laboratory Dept
Krasnodar
E. S. Kameneva
Kuban State Medical University; Regional clinical Hospital No. 2
Russian Federation
Russian Federation
Kameneva Elena S., PhD Med, associate professor at Dept of Polyclinic Therapy with Course of General Medical Practice (Family Medicine), Faculty of Advanced Vocational Training and Retraining; head of the Polyclinic of Specialized Outpatient Treatment Course
Krasnodar
N. P. Belozerova
Kuban State Medical University; Regional clinical Hospital No. 2
Russian Federation
Russian Federation
Belozerova Natalia P., PhD Med, associate professor at Dept of Faculty Therapy; head of the Rheumatology Center at the Polyclinic of Specialized Outpatient Treatment Course
Krasnodar
References
1. Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. Nat Immunol. 2021; 22 (1): 10–18. https://doi.org/10.1038/s41590-020-00816-x
2. Babaahmadi M, Tayebi B, Gholipour NM, Kamardi MT, Heidari S, Baharvand H, Eslaminejad MB, Hajizadeh-Saffar E, Hassani SN. Rheumatoid arthritis: the old issue, the new therapeutic approach. Stem Cell Res Ther. 2023; 14 (1): 268. https://doi.org/10.1186/s13287-023-03473-7
3. GBD 2021 Rheumatoid Arthritis Collaborators. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023; 5 (10): e594–e610. https://doi.org/10.1016/S2665–9913(23)00211-4
4. Galikeeva A. Sh., Akhtyamova S.H., Simonova N. I., Idrisova G.B., Ishtukov R.R. COVID 19 as an additional risk factor for major non-communicable diseases in adults: A retrospective analytic descriptive study. Kuban Scientific Medical Bulletin. 2025; 32 (2): 55–68. (In Russ.). https://doi.org/10.25207/1608-6228-2025-32-2-55-68
5. Schattner A. The Cardiovascular Burden of Rheumatoid Arthritis – Implications for Treatment. Am J Med. 2023;136(12):1143–1146. https://doi.org/10.1016/j.amjmed.2023.09.004
6. Hansildaar R, Vedder D, Baniaamam M, Tausche AK, Gerritsen M, Nurmohamed MT. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol. 2021; 3 (1): e58–e70. https://doi.org/10.1016/S2665-9913(20)30221-6
7. Sylman JL, Mitrugno A, Atallah M, Tormoen GW, Shatzel JJ, Tassi Yunga S, Wagner TH, Leppert JT, Mallick P, McCarty OJT. The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis. Front Oncol. 2018; 8: 78. https://doi.org/10.3389/fonc.2018.00078
8. Dolan RD, Lim J, McSorley ST, Horgan PG, McMillan DC. The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis. Sci Rep. 2017; 7 (1): 16717. https://doi.org/10.1038/s41598-017-16955-5
9. Ma R, Cui L, Cai J, Yang N, Wang Y, Chen Q, Chen W, Peng C, Qin H, Ding Y, Wang X, Yu Q, Shi Y. Association between systemic immune inflammation index, systemic inflammation response index and adult psoriasis: evidence from NHANES. Front Immunol. 2024; 15: 1323174. https://doi.org/10.3389/fimmu.2024.1323174
10. Dziedzic EA, Gąsior JS, Tuzimek A, Paleczny J, Junka A, Dąbrowski M, Jankowski P. Investigation of the Associations of Novel Inflammatory Biomarkers-Systemic Inflammatory Index (SII) and Systemic Inflammatory Response Index (SIRI)-With the Severity of Coronary Artery Disease and Acute Coronary Syndrome Occurrence. Int J Mol Sci. 2022; 23 (17): 9553. https://doi.org/10.3390/ijms23179553
11. Jiang P, Li H, Li X. Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis. Clin Exp Rheumatol. 2015; 33 (1): 115–21. Epub 2014 Dec 22. PMID: 25535750.
12. Movahedi M, Beauchamp ME, Abrahamowicz M, Ray DW, Michaud K, Pedro S, Dixon WG. Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2016; 68 (5): 1089–98. https://doi.org/10.1002/art.39537
13. Ozen G, Pedro S, Holmqvist ME, Avery M, Wolfe F, Michaud K. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Ann Rheum Dis. 2017; 76 (5): 848–854. https://doi.org/10.1136/annrheumdis-2016-209954
14. Antohe JL, Bili A, Sartorius JA, Kirchner HL, Morris SJ, Dancea S, Wasko MC. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy. Arthritis Care Res (Hoboken). 2012; 64 (2): 215–21. https://doi.org/10.1002/acr.20657
15. Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G, Papaioannou S, Deftereos S, Tousoulis D. The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. Eur Cardiol. 2019; 14 (1): 50–59. https://doi.org/10.15420/ecr.2018.33.1
16. Baker JF, England BR, Wysham KD, Sauer B, Joseph AM, Lenert A, Roul P, Xiao R, Gillcrist R, Johnson T, Cannon GW, Duryee M, Thiele GM, Mikuls TR. Associations Between Adiponectin and the Development of Diabetes in Rheumatoid Arthritis. J Clin Endocrinol Metab. 2024; 109 (10): e1839–e1846. https://doi.org/10.1210/clinem/dgae010
17. Baker JF, England BR, George M, Cannon G, Sauer B, Ogdie A, Hamilton BC, Hunter C, Duryee MJ, Thiele G, Mikuls TR. Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis. Ann Rheum Dis. 2021; 80 (5): 566–572. https://doi.org/10.1136/annrheumdis-2020-219140
18. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62 (9): 2569–81. https://doi.org/10.1002/art.27584
19. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010; 376 (9746): 1094–108. https://doi.org/10.1016/S0140-6736(10)60826-4
20. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008; 121 (10 Suppl 1): S9–14. https://doi.org/10.1016/j.amjmed.2008.06.011
21. Hollan I, Meroni PL, Ahearn JM, Cohen Tervaert JW, Curran S, Goodyear CS, Hestad KA, Kahaleh B, Riggio M, Shields K, Wasko MC. Cardiovascular disease in autoimmune rheumatic diseases. Autoimmun Rev. 2013; 12 (10): 1004–15. https://doi.org/10.1016/j.autrev.2013.03.013
22. Rausch Osthoff AK, Niedermann K, Braun J, Adams J, Brodin N, Dagfinrud H, Duruoz T, Esbensen BA, Günther KP, Hurkmans E, Juhl CB, Kennedy N, Kiltz U, Knittle K, Nurmohamed M, Pais S, Severijns G, Swinnen TW, Pitsillidou IA, Warburton L, Yankov Z, Vliet Vlieland TPM. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018; 77 (9): 1251–1260. https://doi.org/10.1136/annrheumdis-2018-213585
23. Pinto AJ, Roschel H, de Sa Pinto AL, Lima FR, Pereira RMR, Silva CA, Bonfá E, Gualano B. Physical inactivity and sedentary behavior: overlooked risk factors in autoimmune rheumatic diseases? Autoimmun Rev 2017; 16: 667–674. https://doi.org/10.1016/j.autrev.2017.05.001
24. Fenton SAM, Veldhuijzen van Zanten JJCS, Kitas GD, Duda JL, Rouse PC, Yu CA, Metsios GS. Sedentary behaviour is associated with increased long-term cardiovascular risk in patients with rheumatoid arthritis independently of moderate-to-vigorous physical activity. BMC Musculoskelet Disord. 2017; 18 (1): 131. https://doi.org/10.1186/s12891-017-1473-9
25. Pedersen BK, Saltin B. Exercise as medicine – evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand J Med Sci Sports. 2015; 25 (Suppl 3): 1–72. https://doi.org/10.1111/sms.12581
26. Benatti FB, Pedersen BK. Exercise as an anti-inflammatory therapy for rheumatic diseases-myokine regulation. Nat Rev Rheumatol. 2015; 11 (2): 86–97. https://doi.org/10.1038/nrrheum.2014.193
27. Brance ML, Di Gregorio S, Pons-Estel BA, Quagliato NJ, Jorfen M, Berbotto G, Cortese N, Raggio JC, Palatnik M, Chavero I, Soldano J, Wong R, Del Rio L, Sánchez A, Brun LR. Prevalence of Sarcopenia and Whole-Body Composition in Rheumatoid Arthritis. J Clin Rheumatol. 2021; 27 (6S): S 153–S160. https://doi.org/10.1097/RHU.0000000000001549
28. Dao T, Kirk B, Phu S, Vogrin S, Duque G. Prevalence of Sarcopenia and its Association with Antirheumatic Drugs in Middle-Aged and Older Adults with Rheumatoid Arthritis: A Systematic Review and Meta-analysis. Calcif Tissue Int. 2021; 109 (5): 475–489. https://doi.org/10.1007/s00223-021-00873-w
29. Mena-Vázquez N, Manrique-Arija S, Ordoñez-Cañizares MC, Redondo-Rodriguez R, Rioja Villodres J, Cano-Garcia L, Godoy-Navarrete FJ, Jiménez Nuñez FG, Diaz-Cordovés Rego G, Ureña Garnica I, Fernández-Nebro A. Relationship between polyautoimmunity and sarcopenic obesity in rheumatoid arthritis patients. Reumatol Clin (Engl Ed). 2022; 18 (9): 531–537. https://doi.org/10.1016/j.reumae.2021.06.002
30. Klein GL. THE EFFECT OF GLUCOCORTICOIDS ON BONE AND MUSCLE. Osteoporos Sarcopenia. 2015; 1 (1): 39–45. https://doi.org/10.1016/j.afos.2015.07.008
31. Baker JF, Giles JT, Weber D, George MD, Leonard MB, Zemel BS, Long J, Katz P. Sarcopenic obesity in rheumatoid arthritis: prevalence and impact on physical functioning. Rheumatology (Oxford). 2022; 61 (6): 2285–2294. https://doi.org/10.1093/rheumatology/keab710
32. van Onna M, Boonen A. Challenges in the management of older patients with inflammatory rheumatic diseases. Nat Rev Rheumatol. 2022; 18 (6): 326–334. https://doi.org/10.1038/s41584-022-00768-6
33. Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD. Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol. 2010; 6 (8): 445–51. https://doi.org/10.1038/nrrheum.2010.105
34. Cano-García L, Manrique-Arija S, Domínguez-Quesada C, Vacas-Pérez JC, Armenteros-Ortiz PJ, Ruiz-Vilchez D, Martín-Martín JM, Redondo-Rodríguez R, García-Studer A, Ortiz-Márquez F, Mena-Vázquez N, Fernández-Nebro A. Sarcopenia and Nutrition in Elderly Rheumatoid Arthritis Patients: A Cross-Sectional Study to Determine Prevalence and Risk Factors. Nutrients. 2023; 15 (11): 2440. https://doi.org/10.3390/nu15112440
35. Manrique-Arija S, Mena-Vazquez N, Ureña I, Rioja J, Valdivielso P, Ginel-Mendoza L, Abad-Sánchez S, Jiménez-Núñez FG, Oliver-Martos B, Fernandez-Nebro A. Cumulative inflammatory burden and obesity as determinants of insulin resistance in patients with established rheumatoid arthritis: cross-sectional study. BMJ Open. 2021; 11 (2): e044749. https://doi.org/10.1136/bmjopen-2020–044749
36. Torii M, Hashimoto M, Hanai A, Fujii T, Furu M, Ito H, Uozumi R, Hamaguchi M, Terao C, Yamamoto W, Uda M, Nin K, Morita S, Arai H, Mimori T. Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis. Mod Rheumatol. 2019; 29 (4): 589–595. https://doi.org/10.1080/14397595.2018.1510565
37. Müller R, Kull M, Põlluste K, Valner A, Lember M, Kallikorm R. Factors Associated With Low Lean Mass in Early Rheumatoid Arthritis: A Cross- Sectional Study. Medicina (Kaunas). 2019; 55 (11): 730. https://doi.org/10.3390/medicina55110730
38. Hansildaar R, Vedder D, Baniaamam M, Tausche AK, Gerritsen M, Nurmohamed MT. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol. 2021; 3 (1): e58–e70. https://doi.org/10.1016/S2665-9913(20)30221-6
39. Shrivastava AK, Pandey A. Inflammation and rheumatoid arthritis. J Physiol Biochem. 2013; 69 (2): 335–47. https://doi.org/10.1007/s13105-012-0216-5
40. Wang W, Yao W, Tang W, Li Y, Lv Q, Ding W. Nonlinear associations of systemic immune-inflammation index with all-cause and cardiovascular mortality in US adults with rheumatoid arthritis. Sci Rep. 2024; 14 (1): 16639. https://doi.org/10.1038/s41598–024–67750-y
41. England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018; 361: k1036. https://doi.org/10.1136/bmj.k1036
42. Fragoulis GE, Panayotidis I, Nikiphorou E. Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment. Curr Vasc Pharmacol. 2020; 18 (5): 431–446. https://doi.org/10.2174/1570161117666190619143842
Review
For citations:
Tikhomirova N.Yu., Zhdamarova O.I., Selimov A.Yu., Eliseeva L.N., Sysoeva I.P., Kameneva E.S., Belozerova N.P. The impact of type 2 diabetes on the cardiovascular system in patients with rheumatoid arthritis. Medical alphabet. 2025;(28):59-66. (In Russ.) https://doi.org/10.33667/2078-5631-2025-28-59-66
Views:
179
JATS XML
Email this article 